Delivery Order SPE2DB22D9239-SPE2DB25FDJ83

Award Date 6/3/25
Potential Completion Date 6/25/25
Potential Value $36K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $36,458.16 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the supply of PERJETA 420 MG/14 ML VIAL 14ML, a specialized oncology medication. The contract is not associated with a set-aside designation. It is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $34,039.68 and has an ultimate completion date of July 19, 2024. The contract is for the delivery of the pharmaceutical product PERJETA 420 MG/14 ML VIAL 14ML, with no set-aside designation. DMS Pharmaceutical Group Inc. holds a significant indefinite...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $45,572.70 and an ultimate completion date of March 17, 2025. The award is for the delivery of 4567394636 - PERJETA 420 MG/14 ML VIAL 14ML, a specialized oncology medication. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business organization. The contract is for the delivery of PERJETA 420 MG/14 ML VIAL 14ML, a pharmaceutical product, with a potential value of $8,509.92 and a completion date of February 23, 2024. The contract does not have a set-aside designation. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler based in Park Ridge, Illinois...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $25,529.76, is for the delivery of PERJETA (420 mg/14 ml) vials to support the recurring medical supply needs of Department of Defense (DoD) healthcare facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a quantity of the pharmaceutical product PERJETA 420 MG/14 ML VIAL 14ML. The potential value of this delivery order is $51,059.52, with a completion date of February 12, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that holds numerous federal contracts and Indefinite Delivery Vehicles (IDVs) to supply pharmaceuticals...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract has a ceiling value of $27,343.62 and a period of performance through February 19, 2025. It is for the procurement of 4567104411 - PERJETA 420 MG/14 ML VIAL 14ML, a specialized oncology medication. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the...
The Defense Logistics Agency awarded a firm fixed price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide 4563188467 - PERJETA 420 MG/14 ML VIAL 14ML. The delivery order has a potential value of $41,385.00 and is scheduled for completion by January 18, 2024. DMS Pharmaceutical Group Inc. is a leading pharmaceutical wholesaler that holds various federal contracts and indefinite delivery vehicles to supply pharmaceuticals and medical products to support...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business located in Park Ridge, Illinois. The $25,529.76 contract is for the supply of 4564110226 PERJETA 420 MG/14 ML VIAL 14ML, with a performance period through April 16, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDV) with the DLA, valued up to $4,999,999 through 2025, which enables the agency to...
This firm fixed-price delivery order was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,254.96 award is for the supply of PERJETA 420 MG/14 ML VIAL 14ML, a specialized oncology drug, to support the recurring medical supply needs of military health facilities worldwide. DMS Pharmaceutical Group holds a larger $499,999,999 indefinite delivery contract (IDC) with the DLA...
  • SPE2DB22D9239
    Indefinite Delivery Contract
  • SPE2DB22D9239-SPE2DB25FDJ83
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of 4,568,462,394 units of the drug PERJETA 420 MG/14 ML VIAL 14ML, with a total ceiling value of $36,458.16 and an ultimate completion date of June 25, 2025.

DMS Pharmaceutical Group Inc. is the prime contractor and has no major subcontractors listed. The company specializes in providing a comprehensive range of pharmaceutical products to federal agencies, with a focus on supplying medical supplies and medications to government healthcare systems. This contract award demonstrates DMS Pharmaceutical Group's robust portfolio of pharmaceutical product deliveries, predominantly to the DLA, and its positioning as a crucial supplier in the federal pharmaceutical supply chain.

The contract does not have a set-aside designation and was awarded without the use of any specific set-aside program.

Generated 9/2/25, 9:45 AM